CVE-2022-4511

Public Exploit
RainyGao DocSys path traversal

Description

A vulnerability has been found in RainyGao DocSys and classified as critical. Affected by this vulnerability is an unknown functionality of the component com.DocSystem.controller.UserController#getUserImg. The manipulation leads to path traversal: '../filedir'. The attack can be launched remotely. The exploit has been disclosed to the public and may be used. It is recommended to apply a patch to fix this issue. The associated identifier of this vulnerability is VDB-215851.

Category

5.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.19%
Third-Party Advisory gitee.com Third-Party Advisory vuldb.com
Affected: RainyGao DocSys
Published at:
Updated at:

References

Link Tags
https://gitee.com/RainyGao/DocSys/issues/I66A3V third party advisory exploit
https://vuldb.com/?id.215851 third party advisory permissions required

Frequently Asked Questions

What is the severity of CVE-2022-4511?
CVE-2022-4511 has been scored as a medium severity vulnerability.
How to fix CVE-2022-4511?
To fix CVE-2022-4511, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-4511 being actively exploited in the wild?
It is possible that CVE-2022-4511 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-4511?
CVE-2022-4511 affects RainyGao DocSys.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.